

Michal Y Chowers

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/62576/michal-y-chowers-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146 papers	9,338 citations	49 h-index	94 g-index
155 ext. papers	10,845 ext. citations	4.9 avg, IF	5.61 L-index

#	Paper	IF	Citations
146	Oral Capsulized Fecal Microbiota Transplantation for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization With a Metagenomic Perspective. <i>Clinical Infectious Diseases</i> , 2021 , 73, e166-e175	11.6	15
145	Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1564-1572.e5	6.9	5
144	Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN.. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	2
143	Improved outcomes of pediatric and adult Crohn's disease and association with emerging use of biologics - a nationwide study from the epi-IIRN. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	2
142	Epidemiology of Inflammatory Bowel Diseases in Israel: A Nationwide Epi-Israeli IBD Research Nucleus Study. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1784-1794	4.5	7
141	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , 2021 ,	13.3	8
140	Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1707-1719	1.5	5
139	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021 , 160, 1452-1460.e21	13.3	15
138	Validation of a semiautomated system for surveillance of surgical site infection after cesarean section. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1-3	2	0
137	Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101503	2.4	3
136	Volume of fluid consumption during preparation for colonoscopy is possibly the single most important determinant of bowel preparation adequacy. <i>Annals of Gastroenterology</i> , 2021 , 34, 705-712	2.2	
135	Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF α therapy in inflammatory bowel disease patients: a report from the epi-IIRN. <i>Gut</i> , 2021 ,	19.2	5
134	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 418-424	5.3	13
133	Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with <i>Clostridioides difficile</i> infection?. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 513-519	3	3
132	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1330-1339	4.5	4
131	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
130	COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S791-S797	1.5	9

129	Intratumoral HLA-DR/CD33/CD11b Myeloid-Derived Suppressor Cells Predict Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1375	5.3	1
128	Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. <i>Gastroenterology</i> , 2019 , 157, 1338-1351.e8	13.3	12
127	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 519-528	18.8	35
126	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2019 , 9, e024222	3	4
125	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. <i>Digestive and Liver Disease</i> , 2019 , 51, 68-74	3.3	14
124	Cell-centred meta-analysis reveals baseline predictors of anti-TNF α non-response in biopsy and blood of patients with IBD. <i>Gut</i> , 2019 , 68, 604-614	19.2	97
123	Association of Vedolizumab Level, Anti-Drug Antibodies, and $\alpha\alpha$ Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 697-705.e7	6.9	70
122	Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. <i>Gut</i> , 2018 , 67, 97-107	19.2	131
121	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 890-898	0.7	41
120	Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 212-218	6.1	40
119	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 1410-1417	1.5	4
118	Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis. <i>Cell Reports</i> , 2018 , 24, 3296-3311.e6	10.6	20
117	Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. <i>Clinical Epidemiology</i> , 2018 , 10, 671-681	5.9	24
116	The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression. <i>Neoplasia</i> , 2017 , 19, 175-184	6.4	17
115	The Role of Heparanase in the Pathogenesis of Acute Pancreatitis: A Potential Therapeutic Target. <i>Scientific Reports</i> , 2017 , 7, 715	4.9	22
114	Differentiation of Pancreatic Cyst Types by Analysis of Rheological Behavior of Pancreatic Cyst Fluid. <i>Scientific Reports</i> , 2017 , 7, 45589	4.9	10
113	Secondary antibiotic resistance of <i>Helicobacter pylori</i> isolates in Israeli children and adults. <i>Journal of Global Antimicrobial Resistance</i> , 2017 , 10, 182-185	3.4	7
112	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 404-408	4.5	66

111	Early histological findings may predict the clinical phenotype in Crohn's colitis. <i>United European Gastroenterology Journal</i> , 2017 , 5, 694-701	5.3	7
110	Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 69-75	6.9	17
109	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 3-25	1.5	1087
108	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 276-282	6.1	75
107	Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 549-555	1.5	60
106	Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. <i>Gut</i> , 2016 , 65, 1132-8	19.2	124
105	Discovery of Biomarkers of Response in Early Drug Development. <i>Journal of Crohn's and Colitis</i> , 2016 , 10 Suppl 2, S560-6	1.5	2
104	Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 655-63	4.7	31
103	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 525-31	1.5	55
102	Optimizing Anti-TNF Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 550-557.e2	6.9	239
101	Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNF α production and secretion and activation of the NF κ B non-canonical pathway. <i>Journal of Neural Transmission</i> , 2016 , 123, 137-57	4.3	3
100	Bowel preparation in "real-life" small bowel capsule endoscopy: a two-center experience. <i>Annals of Gastroenterology</i> , 2016 , 29, 196-200	2.2	9
99	Magnetic resonance enterography or video capsule endoscopy - what do Crohn's disease patients prefer?. <i>Patient Preference and Adherence</i> , 2016 , 10, 1043-50	2.4	19
98	Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1655-61	4.5	9
97	Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 3246-3254	4	9
96	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 781-794	4.7	12
95	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1293-9	6.1	57
94	Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. <i>Gastroenterology</i> , 2015 , 148, 948-957.e2	13.3	121

93	Significance of low level infliximab in the absence of anti-infliximab antibodies. <i>World Journal of Gastroenterology</i> , 2015 , 21, 1907-14	5.6	17
92	The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9 Suppl 1, 27-34	4.2	33
91	Development of the Lhann index to assess digestive tract damage in patients with Crohn's disease. <i>Gastroenterology</i> , 2015 , 148, 52-63.e3	13.3	198
90	Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. <i>Medicine (United States)</i> , 2015 , 94, e673	1.8	14
89	Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015 , 61, 404-7	2.8	8
88	Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 356-64	6.1	58
87	Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 177-84	1.5	22
86	Infliximab-Related Infusion Reactions: Systematic Review. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 806-15	1.5	120
85	Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 522-530.e2	6.9	210
84	Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014 , 38, 491-8	2.4	20
83	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. <i>Gut</i> , 2014 , 63, 1258-64	19.2	214
82	Optimizing anti-TNF treatments in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014 , 13, 24-30	13.6	229
81	Tailoring anti-TNF therapy in IBD: drug levels and disease activity. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 243-55	24.2	131
80	Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 620-8	6.1	136
79	Recurrent small intestinal ileus secondary to valsartan treatment. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48, 462-3	3	2
78	Celiac disease resolution after allogeneic bone marrow transplantation is associated with absence of gliadin-specific memory response by donor-derived intestinal T-cells. <i>Journal of Clinical Immunology</i> , 2013 , 33, 1395-402	5.7	7
77	Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 444-7	6.9	244
76	Taking Crohn's disease personally. <i>Rambam Maimonides Medical Journal</i> , 2013 , 4, e0011	1.8	1

75 Novel therapies for ulcerative colitis **2013**, 124-132

74	Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1639-44	4.5	14
73	Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease. <i>Current Drug Safety</i> , 2013 , 8, 181-5	1.4	26
72	Early histological findings quantified by histomorphometry allow prediction of clinical phenotypes in Crohn's colitis patients. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013 , 35, 95-104		1
71	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1770-6	0.7	76
70	Endoscopic ultrasound for perianal Crohn's disease: disease and fistula characteristics, and impact on therapy. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 311-6	1.5	20
69	Clinical and radiographic presentation of superior mesenteric vein thrombosis in Crohn's disease: a single center experience. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 543-9	1.5	9
68	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 965-90	1.5	592
67	Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1628-33	4.5	67
66	The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 714-22	6.1	45
65	A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. <i>PLoS Genetics</i> , 2012 , 8, e1002559	6	117
64	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. <i>Gut</i> , 2012 , 61, 241-7	19.2	216
63	Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 555-8	1.5	76
62	Prediction of disease complication occurrence in Crohn's disease using phenotype and genotype parameters at diagnosis. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 592-7	1.5	24
61	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. <i>American Journal of Gastroenterology</i> , 2011 , 106, 199-212; quiz 213	0.7	291
60	The immunogenic part of infliximab is the F(ab') ₂ , but measuring antibodies to the intact infliximab molecule is more clinically useful. <i>Gut</i> , 2011 , 60, 41-8	19.2	164
59	Color-coded duplex sonography compared to multidetector computed tomography for the diagnosis of crohn disease relapse and complications. <i>Journal of Ultrasound in Medicine</i> , 2011 , 30, 1691-9 ^{2.9}		9
58	Non-Jewish Israeli IBD patients have significantly higher glutathione S-transferase GSTT1-null frequency. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 2081-7	4	18

57	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1415-22	4.5	395
56	Familial ulcerative colitis in Israeli Jews: its prevalence and clinical severity compared to sporadic disease. <i>Annals of Gastroenterology</i> , 2011 , 24, 285-289	2.2	4
55	Adalimumab level in breast milk of a nursing mother. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 475-6	6.9	87
54	Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 194-8	1.5	61
53	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 355-68	1.5	227
52	Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 367-76	1.5	37
51	Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappa B activation. <i>Immunobiology</i> , 2010 , 215, 304-13	3.4	26
50	Efficacy of anti-TNF in Crohn's disease: how does it work?. <i>Current Drug Targets</i> , 2010 , 11, 138-42	3	14
49	A murine model for the study of molecular pathogenesis of radiation proctitis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 242-50	4	43
48	Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 640-8	6.5	50
47	Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 239-50	5.1	45
46	Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 171-5	4.5	26
45	Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 981-7	6.9	102
44	Hospital-wide methicillin-resistant Staphylococcus aureus control program: A 5-year follow-up. <i>Infection Control and Hospital Epidemiology</i> , 2009 , 30, 778-81	2	14
43	Multislice CT compared to small bowel follow-through in the evaluation of patients with Crohn disease. <i>Clinical Imaging</i> , 2008 , 32, 355-61	2.7	10
42	Neuroimmunology of the gut: physiology, pathology, and pharmacology. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 490-5	5.1	45
41	Functional voltage-gated sodium channels are expressed in human intestinal epithelial cells. <i>Digestion</i> , 2008 , 77, 108-17	3.6	17
40	Flare-up of ulcerative colitis after systemic corticosteroids: a strong case for Strongyloides. <i>World Journal of Gastroenterology</i> , 2008 , 14, 4413-5	5.6	9

39	B-cell clonal diversification and gut-lymph node trafficking in ulcerative colitis revealed using lineage tree analysis. <i>European Journal of Immunology</i> , 2008 , 38, 2600-9	6.1	19
38	Long-standing colonic inflammation is associated with a low prevalence of diverticuli in inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , 2007 , 13, 733-6	4.5	12
37	The patient with recurrent (sub) obstruction due to Crohn's disease. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2007 , 21, 427-44	2.5	12
36	Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 385-9	4	144
35	O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 2396-401	11.5	23
34	Sweet's syndrome in association with ulcerative colitis and dyserythropoietic anemia. <i>Digestion</i> , 2007 , 75, 142-3	3.6	4
33	TNF-857 polymorphism in Israeli Jewish patients with inflammatory bowel disease. <i>International Journal of Immunogenetics</i> , 2006 , 33, 81-5	2.3	13
32	Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells. <i>Liver International</i> , 2005 , 25, 808-16	7.9	26
31	Endosonographic evaluation of perianal fistulas and abscesses: comparison of two instruments and assessment of the role of hydrogen peroxide injection. <i>Journal of Clinical Ultrasound</i> , 2005 , 33, 226-32	1	12
30	Somatostatin analogue treatment attenuates histological findings of inflammation and increases mRNA expression of interleukin-1 beta in the articular tissues of rats with ongoing adjuvant-induced arthritis. <i>Rheumatology International</i> , 2005 , 25, 350-6	3.6	12
29	The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. <i>American Journal of Gastroenterology</i> , 2005 , 100, 338-43	0.7	70
28	Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. <i>Digestion</i> , 2005 , 72, 124-8	3.6	15
27	The month of birth is linked to the risk of Crohn's disease in the Israeli population. <i>American Journal of Gastroenterology</i> , 2004 , 99, 1974-6	0.7	24
26	The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2004 , 8, 417-20		53
25	A Novel Method for WetSEM. <i>Ultrastructural Pathology</i> , 2004 , 28, 29-31	1.3	6
24	Allicin inhibits spontaneous and TNF-alpha induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. <i>Clinical Nutrition</i> , 2004 , 23, 1199-208	5.9	132
23	A Novel Method for WetSEM. <i>Ultrastructural Pathology</i> , 2004 , 28, 29-31	1.3	17
22	Scanning electron microscopy of cells and tissues under fully hydrated conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 3346-51	11.5	196

21	Colorectal cancer screening in patients presenting with an inguinal hernia: is it necessary?. <i>Gastrointestinal Endoscopy</i> , 2004 , 59, 369-73	5.2	9
20	Second capsule endoscopy for patients with severe iron deficiency anemia. <i>Gastrointestinal Endoscopy</i> , 2004 , 60, 711-3	5.2	59
19	Clinical and demographic characterization of Jewish Crohn's disease patients in Israel. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 8-12	3	27
18	Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. <i>Diseases of the Colon and Rectum</i> , 2003 , 46, 929-36	3.1	50
17	Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. <i>American Journal of Medical Genetics Part A</i> , 2003 , 121A, 240-4		25
16	The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. <i>Clinical Gastroenterology and Hepatology</i> , 2003 , 1, 36-43	6.9	89
15	Gamma interferon down-regulates Fer and induces its association with inactive Stat3 in colon carcinoma cells. <i>Oncogene</i> , 2002 , 21, 4997-5001	9.2	24
14	A defined human gastrin sequence stimulates the growth of <i>Helicobacter pylori</i> . <i>FEMS Microbiology Letters</i> , 2002 , 217, 231-6	2.9	11
13	TNFalpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2002 , 19, 327-37	4.7	16
12	Different beta-catenin immunoexpression in carcinoid tumors of the appendix in comparison to other gastrointestinal carcinoid tumors. <i>Pathology Research and Practice</i> , 2002 , 198, 531-6	3.4	15
11	Crohn disease in patients with familial Mediterranean fever. <i>Medicine (United States)</i> , 2002 , 81, 411-6	1.8	45
10	Augmentation of RANTES-induced extracellular signal-regulated kinase mediated signaling and T cell adhesion by elastase-treated fibronectin. <i>Journal of Immunology</i> , 2001 , 166, 7121-7	5.3	15
9	Disaccharides derived from heparin or heparan sulfate regulate IL-8 and IL-1 beta secretion by intestinal epithelial cells. <i>Gastroenterology</i> , 2001 , 120, 449-59	13.3	15
8	Clinical Characteristics of the West Nile Fever Outbreak, Israel, 2000. <i>Emerging Infectious Diseases</i> , 2001 , 7, 675-678	10.2	180
7	West Nile Fever Outbreak, Israel, 2000: Epidemiologic Aspects. <i>Emerging Infectious Diseases</i> , 2001 , 7, 686-691	10.2	121
6	Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. <i>Journal of Immunology</i> , 2000 , 165, 2955-61	5.3	100
5	Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. <i>American Journal of Gastroenterology</i> , 2000 , 95, 3498-502	0.7	67
4	Human gastrin: a <i>Helicobacter pylori</i> --specific growth factor. <i>Gastroenterology</i> , 1999 , 117, 1113-8	13.3	36

3	Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. <i>Gastroenterology</i> , 1998 , 115, 835-40	13.3	183
2	Peripheral T cell response to A-gliadin in celiac disease: differential processing and presentation capacities of Epstein-Barr-transformed B cells and fibroblasts. <i>Clinical Immunology and Immunopathology</i> , 1994 , 71, 75-81		15
1	Scabies-associated angioimmunoblastic lymphadenopathy. <i>Acta Haematologica</i> , 1986 , 76, 166-8	2.7	2